Lee et al. [124] utilized a TRPV1 antagonist, PAC14028, as a topical cream to treat atopic dermatitis and found that it decreased expression of IL-4 and IL-13, suggesting that TRPV1 channels have proinflammatory effects. Here, TRPV1 is linked to atopic eczema.